CN105535031A - 龙须菜提取物的制备方法及龙须菜提取物的应用 - Google Patents
龙须菜提取物的制备方法及龙须菜提取物的应用 Download PDFInfo
- Publication number
- CN105535031A CN105535031A CN201511011252.5A CN201511011252A CN105535031A CN 105535031 A CN105535031 A CN 105535031A CN 201511011252 A CN201511011252 A CN 201511011252A CN 105535031 A CN105535031 A CN 105535031A
- Authority
- CN
- China
- Prior art keywords
- extract
- thallus gracilariae
- thallus
- gracilariae
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000005340 Asparagus officinalis Nutrition 0.000 title abstract 11
- 244000003416 Asparagus officinalis Species 0.000 title 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000001914 filtration Methods 0.000 claims abstract description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 15
- 239000002035 hexane extract Substances 0.000 claims abstract description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002024 ethyl acetate extract Substances 0.000 claims abstract description 10
- 239000003208 petroleum Substances 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 238000009835 boiling Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 25
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 15
- 238000002481 ethanol extraction Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 229960004756 ethanol Drugs 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 5
- 102000011195 Profilin Human genes 0.000 claims description 5
- 108050001408 Profilin Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 abstract description 31
- 241000234427 Asparagus Species 0.000 abstract 10
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 241000206581 Gracilaria Species 0.000 description 6
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 4
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 3
- 102100036721 Insulin receptor Human genes 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- -1 p-nitrophenyl disodium hydrogen phosphate Chemical compound 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000206588 Gracilaria tenuistipitata Species 0.000 description 1
- 241000206611 Gracilariopsis lemaneiformis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明所公开的龙须菜提取物的制备方法:取龙须菜,将龙须菜用石油醚或正己烷进行提取,经过过滤、浓缩后得到龙须菜石油醚提取物或龙须菜正己烷提取物,经上述处理后的龙须菜去除石油醚或正己烷并经过干燥后,再用乙酸乙酯进行提取,经过过滤、浓缩后得到龙须菜乙酸乙酯提取物,经上述处理后的龙须菜去除乙酸乙酯并经过干燥后,再用无水乙醇进行提取,经过过滤、浓缩后得到龙须菜无水乙醇提取物,经上述处理后的龙须菜去除无水乙醇并经过干燥后,再用50%的乙醇进行提取,经过过滤、浓缩后得到龙须菜50%乙醇提取物,所述的提取过程中,条件为室温提取1-5次,每次1-3天,或者在30℃至溶剂的沸点温度范围内,提取1-5次,每次1-5小时,且上述步骤中,所选用的龙须菜与溶剂的质量体积比为1:3-30g/ml。
Description
技术领域
本发明涉及植物提取技术领域,特别是一种龙须菜提取物的制备方法,以及利用该方法获得的龙须菜提取物的具体应用。
背景技术
龙须菜(Gracilarialemaneiformis),又名江蓠,为江蓠属海洋红藻,广泛地分布于我国沿海地区,此外,日本、美国、加拿大、南非和委内瑞拉等国家也有分布。龙须菜因适应性快、生长率高等特点,已成为我国产量第三养殖大型海藻。龙须菜具有广泛的生物活性,《本草纲目》记载:“龙须菜:生东南海边石上。丛生,无枝叶,状如柳根须,长者尺余,白色,以醋浸食之,和肉蒸食亦佳”;“龙须菜,甘,无毒。治瘿结热气,利小便”。《本草求原》中载:“龙须菜,祛内热”。可见,龙须菜具有悠久的食用和药用历史。研究表明,龙须菜具有抗病毒、抗肿瘤、调节免疫、镇痛抗炎、清除自由基及抗氧化等功效。
PTP1B是蛋白酪氨酸磷酸酶家族中的一个经典的非受体型PTP之一,是最早被纯化和确定生物学特性的蛋白酪氨酸磷酸酶,全长约50kDa,在C末端有一段可被切割的由35个氨基酸组成的疏水片段,该片段负责将PTP1B定位在内质网上,然后与激酶胰岛素受体、表皮生长因子受体和血小板源生长因子受体等相互作用使其去磷酸化。对胰岛素受体及其底物的磷酸化水平起着重要的负调控作用,通过抑制PTP1B的活性,有助于提高外周组织对胰岛素的敏感性。也有研究表明,在PTP1B基因敲除小鼠的骨骼肌和肝脏中,胰岛素受体的自身磷酸化增加,而且对胰岛素的敏感性也有提高。无PTP1B小鼠的肥胖倾向明显降低,而且免患饮食诱导性肥胖症。同时也发现,PTP1B功能缺乏的小鼠发育良好,且具有正常的繁殖能力,癌症的发生率也未见提高。因此,PTP1B是目前公认的治疗糖尿病和肥胖症的药物作用靶点,寻找具有成药性的高活性抑制剂对于糖尿病和肥胖症等疾病的治疗有着广阔的应用前景。
而目前上没有龙须菜或其提取物具有抑制蛋白质酪氨酸磷酸酶1B(PTP1B)活性的功能方面的相关报道。
发明内容
本发明是为了解决现有技术所存在的上述不足,提出一种操作简便,过程可控,产出稳定的龙须菜提取物的制备方法,以及通过该方法获得的龙须菜提取物的具体应用。
本发明的技术解决方案是:一种龙须菜提取物的制备方法,其特征在于:所述的方法按照以下步骤进行:取龙须菜,将龙须菜用石油醚或正己烷进行提取,经过过滤、浓缩后得到龙须菜石油醚提取物或龙须菜正己烷提取物,经上述处理后的龙须菜去除石油醚或正己烷并经过干燥后,再用乙酸乙酯进行提取,经过过滤、浓缩后得到龙须菜乙酸乙酯提取物,经上述处理后的龙须菜去除乙酸乙酯并经过干燥后,再用无水乙醇进行提取,经过过滤、浓缩后得到龙须菜无水乙醇提取物,经上述处理后的龙须菜去除无水乙醇并经过干燥后,再用50%的乙醇进行提取,经过过滤、浓缩后得到龙须菜50%乙醇提取物,所述的提取过程中,条件为室温提取1-5次,每次1-3天,或者在30℃至溶剂的沸点温度范围内,提取1-5次,每次1-5小时,且上述步骤中,所选用的龙须菜与溶剂的质量体积比为1:3-30g/ml。
如上所述的制备方法获得的龙须菜提取物在制备预防和/或治疗糖尿病药物中的应用。
如上所述的制备方法获得的龙须菜提取物在制备预防和/或治疗糖尿病保健品或功能性食品中的应用。
如上所述的制备方法获得的龙须菜提取物的抑制蛋白质酪氨酸磷酸酶的活性的应用。
本发明同现有技术相比,具有如下优点:
本发明所公开的龙须菜的提取物的制备方法,操作过程简单,原料获得容易,各环节可控,且产出稳定,利用该方法能够获得龙须菜石油醚提取物、龙须菜正己烷提取物、龙须菜乙酸乙酯提取物、龙须菜无水乙醇提取物和龙须菜50%乙醇提取物,同时本发明还公开了这些龙须菜的有机溶剂提取物在制备预防和/或治疗糖尿病药物中的具体应用,在本技术领域中,还没有任何文献对于龙须菜的有机溶剂提取物具有抑制蛋白质酪氨酸磷酸酶活性作用的相关报道,因此本申请所提出的制备方法以及利用该方法获得的龙须菜提取物,为治疗/预防糖尿病提供了新的思路,具有广泛的市场前景和产业价值。
具体实施方式
下面将说明本发明的具体实施方式。一种龙须菜提取物的制备方法,按照以下步骤进行:取龙须菜,将龙须菜用石油醚或正己烷进行提取,经过过滤、浓缩后得到龙须菜石油醚提取物或龙须菜正己烷提取物,经上述处理后的龙须菜去除石油醚或正己烷并经过干燥后,再用乙酸乙酯进行提取,经过过滤、浓缩后得到龙须菜乙酸乙酯提取物,经上述处理后的龙须菜去除乙酸乙酯并经过干燥后,再用无水乙醇进行提取,经过过滤、浓缩后得到龙须菜无水乙醇提取物,经上述处理后的龙须菜去除无水乙醇并经过干燥后,再用50%的乙醇进行提取,经过过滤、浓缩后得到龙须菜50%乙醇提取物,所述的提取过程中,条件为室温提取1-5次,每次1-3天,或者在30℃至溶剂的沸点温度范围内,提取1-5次,每次1-5小时,且上述步骤中,所选用的龙须菜与溶剂的质量体积比为1:3-30g/ml。
利用上述方法获得的龙须菜提取物在制备预防和/或治疗糖尿病药物中的应用。
利用上述方法获得的龙须菜提取物在制备预防和/或治疗糖尿病保健品或功能性食品中的应用。
利用上述方法获得的龙须菜提取物的抑制蛋白质酪氨酸磷酸酶的活性的应用。
实施例1
166克干燥龙须菜,加入1.8L正己烷回流提取3次,每次3小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到正己烷提取物75mg。
龙须菜自然晾干后继续加入1.5L乙酸乙酯提取3次,每次3小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙酸乙酯提取物138mg。
龙须菜自然晾干后继续加入1.5L无水乙醇提取3次,每次3小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙醇提取物3.43g。
龙须菜自然晾干后继续加入1.5L50%乙醇提取3次,每次3小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到50%乙醇提取物20.85g。
实施例2
500克干燥龙须菜,加入5L正己烷回流提取2次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到正己烷提取物210mg。
龙须菜自然晾干后继续加入4.5L乙酸乙酯提取2次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙酸乙酯提取物408mg。
龙须菜自然晾干后继续加入4.5L无水乙醇提取2次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙醇提取物11.23g。
龙须菜自然晾干后继续加入4.5L50%乙醇提取2次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到50%乙醇提取物61.21g。
实施例3
1000克干燥龙须菜,加入10L正己烷,50℃提取3次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到正己烷提取物380mg。
龙须菜自然晾干后继续加入9L乙酸乙酯,50℃提取3次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙酸乙酯提取物788mg。
龙须菜自然晾干后继续加入9L无水乙醇,50℃提取3次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙醇提取物20.12g。
龙须菜自然晾干后继续加入9L50%乙醇,50℃提取3次,每次4小时,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到50%乙醇提取物111.57g。
实施例4
2000克干燥龙须菜,加入20L正己烷,室温浸泡提取3次,每次3天,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到正己烷提取物750mg。
龙须菜自然晾干后继续加入16L乙酸乙酯,50℃提取3次,每次3天,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙酸乙酯提取物1.31g。
龙须菜自然晾干后继续加入16L无水乙醇,50℃提取3次,每次3天,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到乙醇提取物15.29g。
龙须菜自然晾干后继续加入16L50%乙醇,50℃提取3次,每次3天,合并提取液,减压过滤后,通过旋转蒸发仪减压干燥,得到50%乙醇提取物231.18g。
实施例5
蛋白质酪氨酸磷酸酶1B活性筛选方法:用对硝基苯基磷酸二钠(pNPP)作为底物,以在阳性药物钒酸钠为对照,利用酶标仪进行PTP1B酶抑制剂的高通量筛选,根据PTP1B水解对硝基苯基磷酸二钠(pNPP)的磷酸基团而产生颜色反应来测定PTP1B的活性;酶反应体系组成如下:缓冲液(50mMHEPES,pH7.3,100mM氯化钠,0.1%牛血清白蛋白,和1mM二硫代苏糖醇),PTP1B蛋白,对硝基苯基磷酸二钠(pNPP),蛋白质酪氨酸磷酸酶1B特异抑制剂钒酸钠(100μg/mL);反应体系混匀后在37℃放置30min,用酶标仪测定405波长条件下的吸收值(A),测定结果减去本底值后计算酶活性;
龙须菜正己烷提取物的PTP1B抑制活性测定结果,见表1和表2。
表1.不同浓度的正己烷提取物和对照加入到反应体系后的吸光度
表2.不同浓度的正己烷提取物对PTP1B的抑制率
以抑制率对样品浓度作图,计算IC50。得到正己烷提取物对PTP1B的半数抑制浓度IC50为17.0287±0.0813μg/ml。其他提取物依照此方法,得到了各提取物对PTP1B的半数抑制浓度。
不同龙须菜提取物对PTP1B的实验结果表明,与阳性对照品相比,通过本发明所述方法获得的龙须菜正己烷提取物和50%乙醇具有良好的蛋白质酪氨酸磷酸酶1B抑制剂作用(表3)。
表3不同龙须菜提取物对蛋白酪氨酸磷酸酶1B(PTP1B)的IC50
编号 | 提取物 | IC50 (μg/mL) |
1 | 正己烷提取物 | 17.0287±0.0813 |
2 | 乙酸乙酯提取物 | >100 |
3 | 无水乙醇提取物 | >100 |
4 | 50%乙醇提取物 | 68.6005±0.0927 |
Claims (4)
1.一种龙须菜提取物的制备方法,其特征在于:所述的方法按照以下步骤进行:取龙须菜,将龙须菜用石油醚或正己烷进行提取,经过过滤、浓缩后得到龙须菜石油醚提取物或龙须菜正己烷提取物,经上述处理后的龙须菜去除石油醚或正己烷并经过干燥后,再用乙酸乙酯进行提取,经过过滤、浓缩后得到龙须菜乙酸乙酯提取物,经上述处理后的龙须菜去除乙酸乙酯并经过干燥后,再用无水乙醇进行提取,经过过滤、浓缩后得到龙须菜无水乙醇提取物,经上述处理后的龙须菜去除无水乙醇并经过干燥后,再用50%的乙醇进行提取,经过过滤、浓缩后得到龙须菜50%乙醇提取物,所述的提取过程中,条件为室温提取1-5次,每次1-3天,或者在30℃至溶剂的沸点温度范围内,提取1-5次,每次1-5小时,且上述步骤中,所选用的龙须菜与溶剂的质量体积比为1:3-30g/ml。
2.根据权利要求1所述的制备方法获得的龙须菜提取物在制备预防和/或治疗糖尿病药物中的应用。
3.根据权利要求1所述的制备方法获得的龙须菜提取物在制备预防和/或治疗糖尿病保健品或功能性食品中的应用。
4.根据权利要求1所述的制备方法获得的龙须菜提取物的抑制蛋白质酪氨酸磷酸酶的活性的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511011252.5A CN105535031A (zh) | 2015-12-30 | 2015-12-30 | 龙须菜提取物的制备方法及龙须菜提取物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511011252.5A CN105535031A (zh) | 2015-12-30 | 2015-12-30 | 龙须菜提取物的制备方法及龙须菜提取物的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105535031A true CN105535031A (zh) | 2016-05-04 |
Family
ID=55814956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511011252.5A Pending CN105535031A (zh) | 2015-12-30 | 2015-12-30 | 龙须菜提取物的制备方法及龙须菜提取物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105535031A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101138414A (zh) * | 2007-10-22 | 2008-03-12 | 天津科技大学 | 一种从龙须菜等含胶海藻中同时提取藻红蛋白和琼胶的方法 |
CN104086664A (zh) * | 2014-06-09 | 2014-10-08 | 华南理工大学 | 一种龙须菜多糖提取物及其制备方法与应用 |
-
2015
- 2015-12-30 CN CN201511011252.5A patent/CN105535031A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101138414A (zh) * | 2007-10-22 | 2008-03-12 | 天津科技大学 | 一种从龙须菜等含胶海藻中同时提取藻红蛋白和琼胶的方法 |
CN104086664A (zh) * | 2014-06-09 | 2014-10-08 | 华南理工大学 | 一种龙须菜多糖提取物及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
陆崇玉等: "龙须菜化学成分研究 ", 《中草药》 * |
陆崇玉等: "龙须菜化学成分研究", 《中草药》 * |
顾冬雨: "龙须菜提取物蛋白络氨酸磷脂酶1B抑制活性研究", 《中国化学会第十届全国天然有机化学学术会议论文集》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101782532B1 (ko) | 백지 추출물 또는 이로부터 분리된 퓨라노쿠마린을 함유하는 조류 인플루엔자, 돼지 인플루엔자 또는 코로나 바이러스의 예방 또는 치료용 조성물 | |
Srivastava et al. | Pharmacognostic and pharmacological evaluation of Hyssopus officinalis L.(Lamiaceae) collected from Kashmir Himalayas, India | |
KR20150088414A (ko) | 한약재 수증기 증류 추출물을 유효성분으로 함유하는 염증 예방 또는 치료용 조성물 | |
Chuang et al. | Ancordin, the major rhizome protein of madeira-vine, with trypsin inhibitory and stimulatory activities in nitric oxide productions | |
Chen et al. | The genus Broussonetia: an updated review of phytochemistry, pharmacology and applications | |
Robertovna et al. | A Traditional Medicine Plant, Onopordum acanthium L.(Asteraceae): Chemical Composition and Pharmacological Research. | |
KR20120031041A (ko) | 이고들빼기로부터 분리한 화합물을 유효성분으로 함유하는 간 기능 개선용 약학적 조성물 및 간 기능 개선용 건강기능 식품조성물 | |
CN105535031A (zh) | 龙须菜提取物的制备方法及龙须菜提取物的应用 | |
KR101581240B1 (ko) | 글리시리진 및 리퀴리틴을 함유하는 감초 추출물 제조 방법 | |
KR20140136326A (ko) | 체중 감소용 감태 추출물 및 이의 제조방법 | |
CN103271968B (zh) | 一种红花籽粕提取物的降糖用途 | |
Kumar et al. | Hepatoprotective activity of Adhatoda vasica and Vitex negundo leaf extracts against carbon tetrachloride induced hepatotoxicity in rats | |
CN104147038A (zh) | 具有抗胃溃疡作用的真菌多糖及其组合物 | |
KR20150102833A (ko) | 상백피 추출물로부터 분리한 화합물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물 | |
CN109169091B (zh) | 一种提高三七中三七素含量的方法 | |
CN102119953A (zh) | 地锦草提取物的应用 | |
RU2695661C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ НАСТОЙКИ ИЗ ЛИСТЬЕВ ТОПОЛЯ ЧЕРНОГО, ОБЛАДАЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ШТАММОВ Burkholderia | |
Chen et al. | Process optimization of Syringa oblata Lindl. by response surface methodology and its effect on Staphylococcus xylosus biofilm | |
CN102451251B (zh) | 榅桲果实降血糖有效部位的制备方法及其用途 | |
Mahaveerchand et al. | Environmental, industrial, and health benefits of Moringa oleifera | |
KR101866749B1 (ko) | 항염 활성을 갖는 울금 함유 어간장 | |
KR101062003B1 (ko) | 사방오리나무 추출물 또는 그로부터 분리된 화합물을 유효성분으로 하는 당뇨병 예방 및 치료용 조성물 | |
CN105560313B (zh) | 一种治疗糖尿病的复方金鹳草药物及其制备方法 | |
KR20160091101A (ko) | 옻나무의 피부염 유발 독성물질 제거 법제방법 및 이에 따라 제조된 옻나무 식품 첨가물 | |
KR102479180B1 (ko) | SARS-CoV-2 3CL 프로테아제와 RdRp활성을 억제하는 지유 추출 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160504 |
|
RJ01 | Rejection of invention patent application after publication |